Dyadic International (DYAI) Stock Price, News & Analysis

Company Overview

Dyadic International, Inc. is a biotechnology company that develops microbial protein-production technologies for use in the biopharmaceutical, vaccine, industrial enzyme and food markets. Its platforms are designed to produce proteins efficiently at commercial scale, with potential applications including vaccines, therapeutic proteins, antibodies, enzymes and other biological products.

The company’s principal technology is its C1 expression platform, which uses a proprietary fungal host organism to produce recombinant proteins. Dyadic also develops the Dapibus platform and related technologies intended to support the production of proteins and other biologically derived materials. The company works with commercial, academic and government partners to advance applications of its platforms.

Dyadic was founded in 1979 and is headquartered in Jupiter, Florida. Its activities have expanded from industrial enzyme production into broader biotechnology and biopharmaceutical applications, serving partners and potential customers in North America, Europe and other international markets. Mark Emalfarb, the company’s founder, serves as president and chief executive officer.

Key Stats

• Today's Range: $0.44 to $0.46
• 50-Day Range: $0.40 to $1.08
• 52-Week Range: $0.34 to $1.60
• Volume: 119,257 shs
• Average Volume: 182,297 shs
• Market Capitalization: $17.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Dyadic International Stock Analysis - MarketRank™

Dyadic International scored higher than 38% of companies evaluated by MarketBeat, and ranked 670th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Dyadic International has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Dyadic International has a consensus price target of $3.00, representing about 574.2% upside from its current price of $0.45.

Amount of Analyst Coverage

Dyadic International has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dyadic International are expected to grow in the coming year, from ($0.15) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyadic International is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyadic International is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyadic International has a P/B Ratio of 14.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.72% of the float of Dyadic International has been sold short.

Short Interest Ratio / Days to Cover

Dyadic International has a short interest ratio ("days to cover") of 1.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dyadic International has recently increased by 30.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyadic International does not currently pay a dividend.

Dividend Growth

Dyadic International does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Dyadic International this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dyadic International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,165.00 in company stock.

Percentage Held by Insiders

20.90% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.95% of the stock of Dyadic International is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DYAI
• CIK: 1213809
• Web: www.dyadic.com
• Phone: (561) 743-8333
• Fax: 561-743-8343
• Employees: 5
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Dyadic International: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +575.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.36 million
• Net Margins: -201.43%
• Pretax Margin: -201.43%
• Return on Equity: -2,920.31%
• Return on Assets: -84.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $3.09 million
• Price / Sales: 5.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 14.81

Miscellaneous

• Outstanding Shares: 40,060,000
• Free Float: 31,691,000
• Market Cap: $17.80 million
• Optionable: Optionable
• Beta: 0.96